Abstract
Infection is a major cause of morbidity and mortality in intensive care units (ICU). The impact on prognostic of an inadequate antibiotic therapy is well established. The problem is due to the growing spread of resistant microorganisms, including both Gram-negative and Gram-positive pathogens, especially in the case of ICU-acquired infections. In this context, antibiotics with broad spectrum activity are usually required. Moreover, these antibiotics should reach high concentrations in tissues, especially in lungs, and should exert a bactericidal activity for the most severely ill patients, especially those with bloodstream infections. A frequent problem in clinical practice is the lack of data validating their use in the context of critically ill patients. In the present article, we review the newest antibiotics that could be of interest for severe ICU-acquired infections: tigecycline, moxifloxacine, the newer carbapenems, linezolide and daptomycine. We discuss their approved indications and identify the fields in which they could be used to treat infections acquired in the ICU.
Keywords: New antibiotics, severity, acquired infections, intensive care, ICU-acquired infections, linezolide and daptomycine, spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), bloodstream infections, Haemophilus influenza, Nosocomial bloodstream infections, tetracyclineresistant isolates, Stenotrophomonas maltophilia, pharmacokinetic, alkaline phosphatase, tigecyclin, hemodialysis
Infectious Disorders - Drug Targets
Title: New Antibiotics for Severe ICU-Aquired Bacterial Infections
Volume: 11 Issue: 4
Author(s): Julien Poissy and Eric Senneville
Affiliation:
Keywords: New antibiotics, severity, acquired infections, intensive care, ICU-acquired infections, linezolide and daptomycine, spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), bloodstream infections, Haemophilus influenza, Nosocomial bloodstream infections, tetracyclineresistant isolates, Stenotrophomonas maltophilia, pharmacokinetic, alkaline phosphatase, tigecyclin, hemodialysis
Abstract: Infection is a major cause of morbidity and mortality in intensive care units (ICU). The impact on prognostic of an inadequate antibiotic therapy is well established. The problem is due to the growing spread of resistant microorganisms, including both Gram-negative and Gram-positive pathogens, especially in the case of ICU-acquired infections. In this context, antibiotics with broad spectrum activity are usually required. Moreover, these antibiotics should reach high concentrations in tissues, especially in lungs, and should exert a bactericidal activity for the most severely ill patients, especially those with bloodstream infections. A frequent problem in clinical practice is the lack of data validating their use in the context of critically ill patients. In the present article, we review the newest antibiotics that could be of interest for severe ICU-acquired infections: tigecycline, moxifloxacine, the newer carbapenems, linezolide and daptomycine. We discuss their approved indications and identify the fields in which they could be used to treat infections acquired in the ICU.
Export Options
About this article
Cite this article as:
Poissy Julien and Senneville Eric, New Antibiotics for Severe ICU-Aquired Bacterial Infections, Infectious Disorders - Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/187152611796504854
DOI https://dx.doi.org/10.2174/187152611796504854 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genome Variability in Gram-Positive Pathogenic Bacteria - Impact on Virulence and Evolution
Current Genomics Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Linezolid Induced Skin Reactions in a Multi Drug Resistant Infective Endocarditis Patient: A Rare Case
Current Drug Safety Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development
Current Pharmaceutical Design The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Small Molecule Approaches Toward the Non-Microbicidal Modulation of Bacterial Biofilm Growth and Maintenance
Anti-Infective Agents in Medicinal Chemistry Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Pseudomonas aeruginosa Invades Human Aortic Endothelial Cells and Induces Cell Damage in vitro
Cardiovascular & Hematological Disorders-Drug Targets